Business
Supernus Announces First Quarter 2020 Financial Results
First quarter total revenue of $95.0 million, an 11% increase over 2019First quarter net product sales of $92.5 million, an 11% increase over 2019First
About this update from Supernus Pharmaceuticals, Inc.
[{"type":"text","content":"First quarter total revenue of $95.0 million, an 11% increase over 2019First quarter net product sales of $92.5 million, an 11% increase over 2019First quarter operating earnings of $29.0 million, a 14% increase over 2019On track for launch of SPN-812 at the end of 2020, pending FDA approval. PDUFA date of November 8, 2020 for review of NDAAcquisition of CNS portfolio of US WorldMeds expands and strengthens neurology portfolio with established marketed products and late-stage pipeline. Expected to close in second quarter 2020Partnership with Navitor Pharmaceuticals expands psychiatry portfolio with Phase II program for potential treatment of depression ROCKVILLE, Md., May 05, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today reported financial results for the first quarter of 2020 and associated Company developments\n Commercial Update First quarter 2020 product prescriptions for Trokendi XR® and Oxtellar XR®, as reported by IQVIA, totaled 203,404, a 2% increase over first quarter 2019. Prescriptions Q1 2020 Q1 2019 Change %Trokendi XR160,315 160,940 —%Oxtellar XR43,089 38,580 12%Total203,404 199,520 2% Source: IQVIA First quarter 2020 net product sales were $92.5 million, an increase of 11% over $83.1 million in the first quarter of 2019. As previously disclosed, wholesalers, distributors, and pharmacies decreased their inventory levels of the Company's products in the first quarter of 2019. The Company estimates that this caused net product sales in the first quarter of 2019 to be approximately $10 million lower had inventory levels remained constant, thus favorably impacting year over year net product sales growth in the first quarter of 2020. Net Product Sales($ in millions) Q1 2020 Q1 2019 Change %Trokendi XR$68.6 $63.7 8%Oxtellar XR23.9 19.4 23%Total$92.5 $83.1 11% Supply of Trokendi XR and Oxtellar XR has not been impacted by COVID-19. The Company has adequate inventory on hand for both products to continue to be available to patients. Corporate and Product Pipeline Update SPN-812 - Novel non-stimulant for the treatment of ADHD The Company continues to prepare for the commercial launch of SPN-812 at the end of 2020.The Company remains engaged with the U.S. Food...